Custom Search

News

Friday 01 December 2000

[Efficacy of pefoxacin (abactal) in the complex treatment of patients with pancreonecrosis]

By: Gel'fand BR, Burnevich SZ, Gel'fand EB, Tsydenzhapov ETs, Briukhov AN, Brazhnik TB, Saganov VP, Pukhaev DA.

Antibiot Khimioter 2001;46(5):24-7

The efficacy of pefloxacin in the complex treatment of 28 patients with pancreatonecrosis of various etiology was estimated in a prospective trial. The diagnosis of pancreatonecrosis was verified by the data of the disease clinical progress, laboratory findings and instrumental examination. Pefloxacin (Abactal; LEK) was administered intravenously in a dose of 400 mg every 8 hours (1200 mg) in combination with metronidazole in a dose of 1.5-2.0 g a day intravenously. When indicated 3 days after the start of the pefloxacin therapy, the treatment was switched to the oral use of the drug in the same dosage. The positive clinical effect (cure and improvement) at the end of the treatment with pefloxacin was stated in 78 per cent of the patients in spite of the initial severity state of above 15 APACHE II. It was shown that in the treatment of patients with pancreatonecrosis when the severity state was not above 12 APACHE II the antibacterial therapy with pefloxacin in combination with metronidazole was optimal.

Use of this site is subject to the following terms of use